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Hydrogel design strategies for drug delivery 
Cécile A. Dreiss 
Institute of Pharmaceutical Science, King’s College London, 150 Stamford Street, SE1 9NH 
London, U.K. 
Abstract 
Hydrogels are water-swollen three-dimensional networks made of polymers, proteins, small 
molecules or colloids. They constitute a versatile platform for drug delivery, because of their capacity 
to encapsulate and protect drugs and provide sustained and/or remotely programmable spatial and 
temporal release, and have thus generated a substantial amount of research for the delivery of either 
small active compounds or biopharmaceuticals. This article discusses the features that make hydrogels 
attractive as matrices for delivery and reviews a range of designs, focusing on studies from recent 
years, in particular: “smart” hydrogels (responding to temperature, light, magnetic fields, ultrasounds 
or combined stimuli); recent technologies: 3D printing and microneedles; and closes by discussing 
polymer-free drug delivery systems: peptides, small molecules and colloids.  
 
Introduction 
Hydrogels are water-swollen networks usually formed of polymers, sometimes smaller molecules or 
colloidal particles, either chemically or physically cross-linked. Their interest as drug delivery systems 
(DDS) keeps rising (1)(2) - ca. 20k publications found with the keywords “hydrogel”, “drug” and 
“delivery”, half of them in the last 5 years - including a marked focus for applications in regenerative 
medicine and cell therapy (3) (a field beyond the scope of this review). Hydrogels present a wide range 
of design options in terms of the nature of the constitutive molecules, their functionality (e.g. co-
delivery of multiple drugs (4)(5)(6)(7), simultaneous imaging and therapy (8–10), programmable and 
controlled release (1,11,12), the hierarchy of micro- and nano-environments accessible (hydrophobic 
or hydrophilic), and a plethora of additional possibilities, such as attaching ligands, combining them 
with nanoparticles (NPs), attaching drugs etc; for all these reasons, they provide a versatile platform 
for drug delivery, and some have made it to the clinic (1). 
Conventional drug delivery involves the repeated administration of an active compound to maintain 
therapeutic levels in the body; this compromises patient compliance, efficacy and can lead to side 
effects due to high doses. Research in drug delivery has therefore focused efforts on achieving 
controlled and local drug delivery, using nanostructured systems, such as liposomes, nanoparticles, 
membranes and hydrogels. Hydrogels mostly comprise of water, offering an environment similar to 
natural tissues, tunable mechanical properties matching soft to hard tissues, and a capacity to 
encapsulate drugs, slowing or preventing their degradation, aggregation, prolonging their lifetime, 
while providing sustained release, controlled by diffusion out of or degradation of the matrix, or 
remotely controlled by external/endogenous triggers. Most hydrogels offer a hydrophilic locus of 
solubilisation, and are thus particularly attractive for biopharmaceuticals, a rapidly increasing area of 
new drugs approved, such as recombinant proteins and peptides (13)(14), monoclonal antibodies and 
polynucleotides (15)(16)(17), including siRNAs, an area of particular focus in recent years (18)(19)(20). 
Depending on their architecture however, hydrogels may also solubilise hydrophobic drugs, for 
instance when combined with polymer nanoparticles in nanocomposite gels (21) (22).  
In terms of their architecture, hydrogels can be made from a very large range of building blocks (e.g. 
polymers – usually classified as natural or synthetic -, peptides (13)(16)(23)(24)(17), proteins (13), 
surfactants (25), colloids (26)(27), small molecules (2)(28)(29)…), with different chemistries, different 
arrangement of the building blocks and different types of connections (cross-links), leading, 
effectively, to a myriad of macroscopic and nanoscopic structures, size range, physical properties, and 
function; these characteristics determine which drugs are encapsulated (e.g. small drugs (2), proteins 
(30) or cells (3)(31)) and how they are released. On the macro-scale, hydrogels can be either 
“bulk”/macroscopic gels (suitable for transepithelial route, insertion or injection in the body), or 
microgels (32) (micrometers in size, suitable also for pulmonary and intrabony delivery (1)) or nanogels 
(33)(34)(35) (10-100 nm, suitable for systemic administration and studied for intra-cell delivery (1) 
(34)).  Within the hydrogels, the size of the pores affects their deformability (if they are microscopic) 
and the diffusion of cells, while the mesh size (in the range of 100s of nm) dictates the release of drugs 
through diffusion; this can be altered though degradation and swelling of the matrix, either time-
dependent or triggered. On the smaller length scale, specific interactions between the gel matrix and 
the drug also impact release, whether drugs are covalently conjugated to the polymer or interacting 
via physical bonds (hydrophobic, van der Waals, electrostatic etc). 
A particularly attractive feature of hydrogels is the possibility of injectability (36), either imparted by 
shear-thinning properties, or by in-situ gel formation, which can be triggered by physiological 
temperature or other external stimuli (so-called “smart” or “stimuli-responsive” gels, cf section 1), in 
contrast to implantation in the body through invasive procedures. Both strategies explain the 
attractivity of physical gels vs. chemical gels, also referred to as “supramolecular” gels or “self-healing” 
gels (37), i.e. gels which are sustained by physical interactions instead of covalent bonds; these include 
van der Waals, hydrogen bonds, electrostatic forces and host-guest interactions, typically with 
cyclodextrins (14)(19)(37)(38)(39), or curcubit[n]urils (40). This versatility and inherent dynamic 
nature of crosslinks in physical gels, in addition to the absence of toxic crosslinkers and free radicals 
used in many chemical crosslinking protocols, make them particularly suitable for drug delivery 
applications, and explains why a lot of recent research has focused on supramolecular gels, which also 
constitute the majority of the gel designs discussed in this article. 
This review on hydrogels for drug delivery does not intend to provide an exhaustive synopsis of the 
field - which is vast - but focuses on advances and curiosities of the last few years, with an emphasis 
on gel structure and function.  Accordingly, a large section is devoted to stimuli-responsive gels, with 
selected triggers, followed by two sections on recent technologies, namely, 3D printing of hydrogels 
and hydrogel-based microneedles. The last section discusses polymer-free hydrogels, namely, small 
molecules, colloids, and carrier-free gel drug delivery systems (DDS). While cell delivery is mentioned, 
hydrogels as biomaterials for cell therapy or regenerative medicine is not the subject of this article 
and a review on the topic can be found elsewhere (3). 
 
1. Remote or endogenous triggers to control delivery: “smart” gels  
Over the past decade, research into hydrogels has evolved from inert matrices to “smart” materials, 
namely, materials that change their behaviour in response to one or several stimuli, or their 
combination. While self-assembled surfactant aggregates offer an ideal platform to craft dynamically 
responsive gels (25), the majority of drug delivery devices are based on polymers, due to a larger 
solubilisation locus and safety profiles. Responsiveness is advantageous in the area of delivery, as it 
enables the controlled and targeted release of a payload (41); growing clinical evidence supports the 
value of more complex release profiles, such as patient-specific kinetics, on and off on-demand 
release, pulsatile (11), or sequential release of different therapeutics (42). Conventional triggers 
include pH and temperature; the former, which has been known well before the concept of “smart” 
DDS was developed, is not covered here. The explosion of so-called “thermogels”, mostly in tissue-
engineering applications, but also for drug delivery, justifies a mention here. While substantial effort 
has gone into smart materials, it is worth noting that clinical translation remains in its infancy, with 
most clinical treatments still delivered passively at set times, and current challenges lying in the 
penetration of the activation signal, delivery and retention at the target site, control of the trigger in 
vivo, and inherent materials complexity (11). The most straightforward design relies on 
“nanocomposite gels” (21), a hydrogel matrix acting as the actuator (i.e. undergoing physical change), 
as well as potentially acting as the drug solubilisation locus, while embedded nanoparticles act as the 
transducing material (receiving the signal and converting it into a stimulus); however, other designs 
have been proposed too and, while the focus here is on macroscopic gels, stimuli-responsive injectable 
nanogels (33)(43) and microgels (32) are also emerging. 
 
Figure 1. (A) Schematic diagram illustrating temperature-induced gelation and further dissolution of 
nanocomplex hydrogels based on the tumour necrosis factor-related apoptosis-inducing ligand 
(TRAIL), a homotrimeric type 2 transmembrane protein-ligand belonging to the TNF cytokine family, 
and superparamagnetic iron oxide nanoparticles SPIONs (T/S). The T/S nanocomplex solution, 
containing negatively charged poly(organophosphazene) (PPZ), positively charged TRAIL, and 
hydrophobic SPIONs, turns into a hydrogel at physiological temperature (37C). Multiple magnetic 
hyperthermia therapy (MHT), a technology based on the energy conversion of SPIONs under an 
alternating magnetic field (AMF) can enhance the release at mild temperatures (43C). Reproduced 
from (27) (B) Example of light as a trigger: the irradiation at  = 365 nm induces the isomerization of 
the azobenzene (Azo) attached to a model drug, weakening the binding affinity between Azo and -
cyclodextrin (-CD), releasing Azo from the cavity of -CD, which is tethered to a tetra-PEG hydrogel 
network, making the release rate photoresponsive. Reproduced from (14) 
 
1.1. Thermogels 
Thermally triggered drug delivery is the most traditional and easily implemented stimulus and the 
literature utilising this trigger is vast (44). Typically, thermogels rely on the existence of a phase-
transition between room temperature and physiological temperature, e.g. a lower critical solution 
temperature (LCST), such as poly(N-isopropylacrylamide) (PNIPAM) or poly(oligoethylene glycol 
methacrylate) (POEGMA), or a volume phase transition temperature (VPTT) (45). This transition is 
usually actuated by the change in temperature occurring from contact of the material with the body, 
e.g. after injection, enabling in practice the in-situ gelation of the material, thus used as a depot 
formulation. The field of thermogelling polymers is thriving, for a range of biomedical applications not 
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limited to drug delivery, in particular tissue engineering and cell therapy (3)(46)(47)(48), and are not 
covered here. More recent developments, as discussed in the next sections, rely on encapsulating, 
within the thermo-responsive hydrogels, a material that locally generates heat, in response to an 
external trigger, thus inducing a phase transition; NIR, for this purpose, is attracting a lot of interest, 
based on the surface plasmon resonance effect (SPR), typically of gold nanoparticles or other metallic 
NPs, such as platinum NPs (49) or copper sulfide (50)(51). In this case, the external trigger that induces 
a phase transition may be a gel-sol transition, which enables the release of a cargo. 
An original application of a thermogelling polymer based on PPG, PEG and tetraphenylethene (TPE) – 
a typical chromophore with aggregation-induced emission (AIE) - was proposed for the in vivo drug 
release monitoring of drug concentration and matrix erosion, based on the concept of AIE (52). AIE 
relies on aggregation-dependent fluorescence emission, allowing the non-invasive monitoring of drug 
concentration to maintain dosage in the therapeutic window.  
An original thermogelling construct was proposed by Zhang et al (27) (Figure 1A), combining the 
thermally-triggered gelation of poly(organophosphazene) (PPZ), and the multiple magnetic 
hypothermia (MHT)-induced release of TRAIL (tumour necrosis factor-related apoptosis-inducing 
ligand), a promising monotherapy strategy for cancer, but limited by its short biological half-life. The 
design involved positively charged TRAIL and oleic acid-coated SPIONs (superparamagnetic iron oxide 
nanoparticles) nanoparticles, interacting with negatively charged PPZ. The construct assembled into 
weak gels upon injection at body temperature, while the release of TRAIL was enhanced by MHT-
mediated gel dissolution at higher temperature during hyperthermia (Figure 1A). 
Focusing on the role of chirality to design thermogelling polymers, Mao et al (53) explored the 
stereocomplexation of complementary chiral blocks, with constructs based on an enantiomeric 
mixture of poly(D-lactic acid((PDLA)/PEG diblock and poly(L-lactic acid(PLLA))/PEG; the polymers 
exhibited multiple gel-sol-gel transitions upon heating, which were rationalised by small- and wide-
angle X-ray scattering, and used to tune the release of the cancer drug doxorubicin (DOX). 
Using heat-induced phase transition as the response of another trigger, a flexible patch for 
transdermal delivery was developed by Evanghelidis et al., combining PNIPAM with a microstructured 
heater based on an electrospun polymer fiber network covered with a thin gold layer and attached to 
flexible PET substrates (45). When submitted to a 3V current, the patch heated up and released a 




Figure 2. (A) An azobenzene (Azo)-containing cyclic dipeptide (PAP-DKP-Lys) acts as a photoresponsive 
low Mw gelator (LMWG), based on known 2,5-diketopiperazine-based gelators, but replacing the 
phenyl rings with trans-Azo. The hydrogel undergoes a gel-sol transition upon irradiation at  = 365 
nm due to the photoisomerisation of Azo; the gel reforms upon irradiation with blue light. Polyacids, 
such as DNA, may further stabilise the fibres and be released upon irradiation. Reproduced from 
(17)(B) Schematic illustration of the fabrication of supramolecular gel responsive to NIR irradiation 
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and its application for repeated photothermal-chemotherapy with one-dose injection. The gel is based 
on the conjugated polymer (poly(N-phenylglycine) (denoted here as PPG) grafted with poly(ethylene 
glycol) (PEG) side-chains, which complex with -cyclodextrin, forming pseudopolyrotaxanes (PPR) that 
act as cross-links for the network. Under NIR irradiation, the conversion of light into heat leads to the 
melting of the gels, due to weakening of the inclusion complexes, inducing the release of an 
encapsulated drug (DOX). Reproduced from (54). 
1.2. Photo-controlled release: light and NIR 
Light offers a number of advantages as a trigger: low-cost, ease of tunability of wavelength and 
intensity, spatiotemporal control, and a wide range of chemistries available to design photo-
responsive hydrogels, as reviewed elsewhere (44). Light in the UV (10-400 nm) and visible (390-700 
nm) range however has very low penetration (due to high absorption) and can damage tissues as much 
lower power than NIR; it is therefore limited to near-surface tissues, transdermal delivery (55), or 
following a surgical procedure using a standard clinical blue light (400-500 nm, 400-600 mW·cm-2), for 
instance to induce clinically relevant fast gelation (56). The principles of light as a trigger often relies 
on the use of photo-actuated bond-isomerisation, typically with coumarins, spiropyrans, azobenzene, 
(44). For instance, the UV-dependent host-guest complex formation between azobenzene and -
cyclodextrin can be exploited to tune gel formation or breakage, and thus the release of a hydrophilic 
payload from a PEG-based, such as a short peptide, as demonstrated by Anseth et al. (14) (Figure 1B). 
The photoisomerization of azobenzene was also exploited in the design of low molecular weight 
gelator (LMWG) based on the 2,5-dikitopiperazine motif (17), which rely on the hydrogen bonds 
provided by the heterocycle and - stacking of non-polar rings. Replacing the phenyl with trans-
azobenzenes retains the gelation mechanism, binding long dsDNA oligomers inside the fibrous 
network, but can be switched with light when isomerised into the polar and non-planar cis-
azobenzene, thus releasing DNA (Figure 2A). An original design was proposed by Wang et al (57), who 
developed a photoresponsive gel based entirely on a recombinant protein, by stitching together the 
photoreceptor C-terminal adenosylcobalamin binding domain (CarHc) proteins. The polymeric CarHc 
proteins assemble into a gel in the presence of adenosylcobalamin in the dark and disassemble upon 
exposure to light, providing a facile mechanism for recovery/release of stem cells and proteins. Finally, 
light actuation can also rely on the incorporation of metallic NPs that generate heat upon light 
irradiation and can induce a volume transition in a thermoresponsive polymer, as mentioned in the 
previous section. This approach was adopted by Kim et al. in transdermal patches based on gel 
nanocomposites of poly(N-isopropylacylamide-co-vinyl-2-pyrrolidinone) beads and magnetite in an 
alginate template, which were actuated by blue light of 47.5 mW·cm-2 (55); the light-triggered release 
could be modulated by adjusting exposure time and light intensity. 
For in vivo applications, NIR is more attractive than other ranges of wavelengths from the 
photochemical spectrum due to deeper tissue penetration (ca. 2 mm through skin) and higher 
biosafety. For cancer therapy in particular, where localised therapeutic approaches with high efficacy 
and specificity and low adverse effects are needed, NIR-light responsive drug-loaded hydrogels are 
attractive. NIR-responsiveness typically relies on the use of nanocomposite gels with metal-based 
nanoparticles displaying NIR plasmon resonance, such as platinum, copper sulfide (50)(58)(59) or 
carbon-based materials. Recently, 2-dimensional NIR phothermal agents, such as graphene oxide (60), 
black phosphorus (BP) (61) and MoS2 (62), have also received attention due to their excellent NIR 
absorption and large specific area. For instance, Qiu et al (61) reported the precision delivery of cancer 
drugs to a tumour site by NIR-induced decomposition of a nanocomposite agarose gel containing BP. 
BP presents a high photothermal conversion efficiency and a tunable, direct energy band gap. By 
converting light to energy, the gel could reversibly undergo on-demand hydrolysis and softening, 
releasing a loaded drug (DOX) from the matrix at a specific site, with gel melting being highly 
dependent on the power of the laser (between 1-3 W·cm-2). Wu et al. developed a NIR responsive gel 
based on a short thermoresponsive peptide (NapGFFYD) with embedded PEGylated 2D niobium 
diselenide (NbSe2) as the NIR photothermal agent, in a move towards increased biocompatibility (23).  
Leaking of nanoparticles out of hydrogel matrix or their aggregation compromise the efficacy of 
photothermal therapy (PTT). Zeng et al. addressed this issue by modifying gold nanorods with 
polydopamine, inspired by the adhesive properties of mussel (59), thus tethering the gold nanorods 
within the thermoresponsive matrix comprised of -glycerolphosphate-bound chitosan and 
dopamine-modified alginate. An alternative strategy, which circumvents the use of nanocomposite 
gels, is the use of conjugated polymers (CPs) in the gel structure. CPs are versatile materials that are 
attracting increasing interest in particular for bioimaging applications (63)(64)(65). Liu et al for 
instance exploited the well-known host-guest interaction between PEG and -cyclodextrin to build 
hydrogels (66), where PEG chains were grafted on a CP backbone (poly(N-phenylglycine, PNPG), 
endowing the gel with high photothermal conversion efficiency (=52.6%) (54) (Figure 2B), which 
allowed the triggered release of DOX. The host-guest complexes acting as cross-links to the network 
impart shear-thinning properties and thus injectability. The same building blocks were used by Ruan 
et al (67), using nanocomposites of PNPG and PEG (where PEG may be simply tethered by PNPG 
polymers via hydrogen bonds and physical entanglements), subsequently incorporated in a gel by the 
addition of -cyclodextrin. The gels had a broad NIR-I (650-900 nm) and NIR-II (1000-1700 nm) 
absorption and showed high photothermal conversion efficiency (ca. 40%); the chemotherapeutic 
cisplatin could be repeatedly released upon subsequent cycles of NIR irradiation. CP can also be 
prepared as nanoparticles (64), and incorporated into a thermoresponsive gel matrix, as in the 
example by Wu et al (68), where NPs or films based on poly(diketopyrrolopyrrole-alt-3,4-ethylene-
dioxythiophene) were incorporated into a PNIPAM gel and were able to release a drug on demand via 
NIR irradiation.  
Many of the designs described in this section rely on the use of thermosensitive polymers, which 
shrink upon NIR-triggered heat generation. A different approach was adopted by Anugrah et al, who 
exploited the capacity of indocyanine green (ICG) to generate reactive oxygen species (ROS) when 
irradiated by NIR, which can then cause oxidative damage on weak covalent bonds such as redox-
sensitive diselenides (Se-Se) (69). The gel, based on alginate, involved the functionalisation of alginate 
with norbornene groups and the introduction of diselenide-tetrazine (Se-Tz) crosslinkers to produce 
NIR-responsive linkages through a click reaction. NIR-irradiation triggered the rupture of Se-Se bonds, 
enabling the modulated release of encapsulated DOX, based on power density (1-2 W·cm-2). 
While the systems presented in this section show promise, they remain proof-of-concept studies. 
Amongst the challenges is the development of photochemical reactions and processes that are fast, 
efficient, and activated by low-energy (long) wavelengths. 
1.3. Magnetic gels 
Magnetic fields represent another method for external activation of drug release, usually relying on 
the incorporation of superparamagnetic NPs into the hydrogels, and the use of either static or 
alternating magnetic fields. Classically, SPIONs, NPs of 5-20 nm in size, have been extensively used for 
this purpose, due to their biocompatibility, precisely controllable composition and size, and 
degradation into nontoxic iron species. The application of a static magnetic field can be employed to 
remotely mechanically deform a ferrogel, resulting in fluid convection and release of a payload. For 
instance, Mooney et al. demonstrated that they could regulate release rates from a ferrogel by tuning 
the magnetic signal; specifically, they developed a SPION-containing biphasic alginate gel (42,70) 
(Figure 3A) to induce the triggered release of a payload, after a delay of 5 days, and achieved a payload 
690- to 1950-fold higher than the unstimulated baseline values; the design proved particularly 
efficient to achieve a sequential payload release, by tuning the frequency (42). The optimization of 
pulsatile profiles may be particularly beneficial in chemotherapy to maximise anticancer toxicity, 
reduce off-target side effects and address adaptive resistance, as shown recently by Kennedy et. al 
(12), who systematically investigated the timing and rate of the magnetic stimulation with the same 
biphasic alginate gels (42,70)(Figure 3A), incorporating the chemotherapeutic mitoxantrone, and 
comparing for instance the impact of continuous vs. pulsatile delivery on the survival of melanoma 
cells (Figure 3B-C). An enhancement of the effect of magnetic fields can be achieved by incorporating 
macropores, for instance by introducing gelatin particles which melt at physiological temperature, 
which result in an increased deformation induced (71). 
  
Figure 3. Magnetically responsive hydrogels enabling pulsatile chemotherapeutic delivery profiles (A) 
A schematic of the biphasic ferrogel fabrication process. The biphasic ferrogels were made of alginate 
crosslinked with 1-ethyl-3-(dimethylaminopropyl)carbodiimide (EDC) contain iron oxide powder, 
which is concentrated to one side of the gel, with the use of magnets. The gels were then left to swell, 
frozen at −20 °C to form ice crystals, and finally lyophilized to evaporate the ice crystals, leaving pores. 




constant delivery profiles: (B) quantification of live cells after constant (s1) or various pulsatile (s2-s4) 
delivery profiles immediately after treatment (left, blue) and after a day of recovery (right, red). (C) 
Left: Normalized cell index (melanoma cell population) vs time when exposed to no mitoxantrone 
(dashed black), constant mitoxantrone concentration (s1, solid black), and a pulsed mitoxantrone 
profile (s3, solid green). Right: Zoomed-in index vs time for cells exposed to pulsatile schedule s3. Blue 
rectangles indicate where the mitoxantrone pulses are “on” for the s3 condition. Reproduced from 
(12).  
Injectability being an attractive feature, SPIONs have also been embedded in nano- or micro-gels; 
shortcomings, however, are linked to fast release - even in the absence of activation - and the rapid 
sequestration of gel particulates by the lymphatic system (72). To overcome this leakage, microgels 
have been incorporated into in-situ forming hydrogels, together with SPIONs. Campbell et al. for 
instance developed thermoresponsive microgels prepared by the co-polymerisation of NIPAM and N-
isopropylmethacrylamide that undergo a 90% decrease in volume when heated; AMF pulses increased 
the release rate of 4 kDa FITC-dextran by a factor of 4, with an enhancement that persisted over days 
(72). Departing from the widely used SPIONs, Yassine et al used microfluidics to incorporate 
anisotropic iron nanowires (FeNWs, with dimensions 500 x 45 nm) into PNIPAM microgels; these 
gelled in situ and achieved 70% drug release using repeated pulses of 20 kHz and a power 5-fold lower 
than conventional AFM, exploiting frictional heat generation (73), therefore demonstrating a better 
potential for translation to the clinic where magnetic fields are in the few kHz/MHz range and with a 
lower power than fields typically used in research. Exploiting other heating mechanisms, gold NP films 
have also been used in PNIPAM hydrogels, where the heat is generated via the induction of eddy 
currents, resulting from the collective conductivity of the supra-molecular gold film structure (74); the 
long-term stability of gold in-vivo is advantageous (compared to SPION which can degrade and oxidise 
over time), while AMF overcomes the depth penetration issue linked with NIR-activation.  
1.4. Healing sound: ultrasounds as a trigger 
Compared to light, ultrasounds (US) offer highly effective penetration into soft tissues and can trigger 
drug release either through thermal or mechanical effects generated by cavitation phenomena or 
acoustic convection forces. US activation is usually irreversible, i.e., it does not enable the on-off 
control offered by other triggers (75). For this reason, self-healing polymers are advantageously used 
with this trigger. Huang et al. for instance proposed Fe3+-[PEG-Dopa] hydrogels based on mussel-
mimetic metal-catechol coordination bonds, offering intermediate bond strength, balancing robust 
mechanical properties with the possibility of disruption by US (76). Sun et al. exploited double-
network hydrogels, where one network provides mechanical stability, while the other is disrupted by 
US, inducing the triggered release of drugs linked to the polymers by dynamic covalent bonds (77). 
The weak physical connections formed in host-guest complexes (a strategy previously mentioned, e.g. 
Figure 1B) have also been exploited in a construct based on PEG end-modified with either adamantane 
(Ada) and -cyclodextrin (78). The mechanical distortion of the -CD cycle results in the break-up of 
the Ada: -CD inclusion complexes, hence the break-up of the gel connections and the release of 
proteins embedded in the gel structure. 
The strongest promise of US perhaps lies in their use for transdermal delivery, as they have been 
shown to be particularly advantageous to enhance transdermal delivery, disrupting the intercellular 
lipid bilayer structures in the stratum corneum, thus improving the permeability of the skin. This effect 
was capitalized on in diclofenac sodium (DS) patches, where burst release was avoided by using the 
“nanocomposite gel” strategy, with the drug loaded in polyester microcapsules, themselves 
embedded in a four-armed PEG hydrogel patch (79). In this case, US work both as a penetration 
enhancer and a trigger for the release. Hydrogels have been shown to enhance skin permeability when 
used as a coupling medium with low frequency ultrasound, resulting in increased localized transport 
regions (80). 
1.5. Other stimuli 
An original and less widely studied trigger for drug delivery relies on the response to mechanical forces 
(compression, tension or shear), either physiological or externally applied, and has been reviewed 
recently (81). Di et al for instance developed a microgel-embedded elastomer; DOX could be released 
from the microgels through stretching, as the spherical microgels become ellipsoidal in shape, 
increasing the surface, and thus the release rate (82).  Bioresponsive materials represent another 
promising area of development; these hydrogels can be actuated by biological cues or pathological 
signals, with enzymes (83), glucose concentration (84)(85)(86), ATP/ATPase (87), and have been 
reviewed recently (88). Examples of bioresponsive gels are discussed in the following sections, and 
Figures 4 and 6. 
 
Figure 4. Illustration of the fabrication and properties of a dual responsive hydrogel based on a self-
sorting double network (SDN), which responds both to adenosine triphosphate (ATP) and sarcosine. 
(A) Schematic representation of the post-assembly fabrication strategy for the construction of the 
SDN hydrogel. The additional components (sarcosine oxidase (SOx) and Ca2+ ions) are sequentially 
added to the SDN hydrogel composed of (B) Phos-cycC6 and BPmoc-F3. (C) AND logic gate-type 
response (gel–sol transition) of the multicomponent hydrogel to ATP and sarcosine. (D) Schematic 
representation of controlled fluorescein labelled immunoglobin G (Fl-IgG) release experiments. (E) 
Photographs of the multicomponent hydrogels encapsulating Fl-IgG before and after the addition of 
ATP and/or sarcosine (taken under UV light in a dark room). (F) Fl-IgG release profiles from the 






Responsiveness to more than one stimulus can give finer control over release kinetic profiles, enabling 
multiple delivery of different payloads, while also opening the way to theranostics, i.e. 
sensing/imaging combined with therapy (90). For instance Cao et al (91) reported nanogels comprising 
the hydrophilic poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA) and hydrophobic 
photocleavable o-nitrobenzyl (ONB), which enabled the controlled co-delivery of a hydrophobic cargo 
from the lipophilic cores (via pH, UV and temperature) and a hydrophilic cargo linked to PDMAEMA 
via disulfide junctions (through redox activation). Tanaka and co-cowers (89) recently proposed an 
original design based on self-sorting double-networks (SDN) based on Phos-cycC6/Ca2+ and BPmoc-
F3/Sox as the gelator pair, shown previously to orthogonally self-assemble (92). The hydrogel was 
dually responsive to adenosine triphosphate and sarcosine, programmable in an AND logic gate 
fashion, which enabled the controlled release of an antibody (89) (Figure 4). Combining light and 
biological triggers, Wang et al (90) fabricated carbon dots-embedded microgels, where carbon dots 
act as upconversion fluorescent probes; the delivery system can simultaneously detect glucose (using 
NIR light) and deliver insulin as a response. 
A new level of multi-stimuli responsiveness was proposed by DeForest et al (24), who reported a 
modular framework based on a library of peptides which, through the connectivity of orthogonal 
stimuli-labile moieties acting as cross-links for the network, respond to a range of environmental cues 
(enzyme, reductant, light), inducing the sequential and spatiotemporally varied release of 
encapsulated cells or proteins. By controlling the molecular architecture, this platform provides 
biocomputational capacity through the combinations of Boolean YES/OR/AND gates, enabling the 
tailored, user-specific release of therapeutics triggered by environmental cues. 
To conclude this section on “smart” hydrogels, it must be acknowledged that while the versatility and 
sophistication in designs and functionalities reported in the literature to date is admirable, the 
inherent complexity of the fabrication and control makes translation to the clinic challenging. While 
many of these gels have shown success in animal models, very few have proceeded to clinical trials. 
Further discussion of the successes, challenges and future directions of “smart” materials can be found 
in this review (11).  
2. 3D printing of hydrogels 
With the increasing focus on individualised medicines with tailored doses, there has been a rising 
emphasis on bespoke methods of preparing medicines at the point-of-care. In this context, 3D printing 
(3DP, also referred to as “additive manufacturing”) is an emerging technology that allows the 
fabrication of complex, three-dimensional objects from computer-aided design (CAD). The structure 
is built layer-by-layer from a series of thin horizontal cross-sections, circumventing the use of moulds, 
thus giving a high degree of flexibility in the design. In 2015, the FDA approved SPRITAM, a rapidly 
dissolving levetiracetam tablet for oral suspension, demonstrated the power of 3DP technology to 
rapidly manufacture dosage forms on-demand, fuelling interest in this technology (93). The use of 
hydrogels with 3DP is emerging, and, similarly to the use of microfluidic techniques to generate 
microgels (30)(31), has been particularly focused on applications in regenerative medicine, for the 
manufacture of complex tissues where different cell types can be deposited within a single construct; 
there are however some examples of 3D printed gels for drug or gene delivery. The use of 3D printing 
has been quite notable for instance in the field of wound healing to design hydrogel-based skin 
substitutes with complex nanostructured layers (94), which can incorporate growth factors (46) or 
NSAIDS such as lidocaine (95).  
Polymer solutions can be used as “bioinks”, provided that they are shear-thinning, and that gelation 
can be triggered post-extrusion, either by chemical cross-linking or a physical trigger (such as 
temperature). This technology has been envisaged for instance in ophthalmic drug delivery, to build 
drug delivery devices that can address the challenges of delivery to the back of the eye, e.g. with 
implantable pump systems (96), or Micro-Electro-Mechanical Systems (MEMS), with drug-infused 
hydrogels (96). 3DP is also being employed to manufacture micro- and nano-robots, or 
“microswimmers”, which could find applications in future diagnostic and targeted delivery 
applications, for instance to reach confined inner compartments of the body. Microswimmers belong 
to the class of “Active Matter”, a novel class of non-equilibrium materials, which consume energy and 
generate directed motion. Biodegradable microrobots have been made using 3DP from the two-
photon polymerisation of photocrosslinkable hydrogel gelatin mathacryloyl (GelMA), decorated with 
magnetically responsive nanoparticles (97), which can be designed to respond to pathological 
concentrations of metalloproteinase-2 (MMP-2) by swelling (due to gelatin target cleavage sites), thus 
releasing an embedded cargo (8,97) (Figure 5). In addition to printing a drug matrix, 3DP technology 
can also be employed to construct moulds for casting the drug delivery device using soft lithography 
techniques (96). 
Recent examples of hydrogel drug matrices using 3DP include the printing of lactose-crosslinked 
gelatin scaffolds for the sustained release of dexamethasone (98), a printed pill formed by the reaction 
between two complementary 4-arm PEG polymers with crosslinkable end-groups to load prednisone 
and bovine serum albumin (99), and discs from thermogelling Polaxamer 407 for the delivery of 
paclitaxel and rapamycin (100). In the latter example, the thermogelling sols were extruded into thin 
solid discs, then dehydrated, enabling convenient handling, storage and insertion into the peritoneal 
cavity post-surgery, for the prevention of postoperative peritoneal adhesion (100). 
While the use of 3D printing technology for tissue engineering falls outside the scope of this review, 
artificial tissue mimics can indeed be created to overcome the challenge of precise spatio-temporal 
delivery of signalling molecules; 3D printing for cartilage and osteochondral tissues engineering have 
been recently reviewed (101). The gene of interest and its delivery vector can be incorporated into a 
hydrogel-based bioink, offering a promising platform for the localized, precise presentation of 
biotherapeutics. A recent example of such a gene-activated bioink (GAB) was achieved by engineering 
pore-forming methylcellulose/agarose-based bioinks to modulate the delivery of vector-plasmid 
complexes to stem cells (102). This bioprinting strategy is promising to generate a wide range of 
complex tissues, organs, and organ-on-a-chip (OoC), which are seeing an increased interest as 
alternatives to animal testing. An OoC is a multi-channel microfluidic device that allows continuous 
perfusion of chambers containing multiple cellular microenvironments, thus mimicking a 
physiologically relevant in vivo environment (103). These models have become extremely useful for 
high throughput screening and drug toxicology (93) and are often based on hydrogels which best 
mimic the cellular environment (104,105). 
Host-guest supramolecular chemistry has been combined with 3D printing by the group of Burdick, 
who proposed a platform based on a mixture of hyaluronic acid modified with either adamantane or 
-cyclodextrin to achieve injectable, self-healing gels that can be used as bio-inks. Improved 
mechanical properties can be attained by modifying HA with methacrylate and UV-induced 
photopolymerisation in the presence of a radical-generating photoinitiator (39,106). 
The fabrication of 3D hydrogels is conveniently combined with two-photon polymerization 
microfabrication (TPPM), a highly precise manufacturing technology, to obtain 3D microstructures 
with high resolution on the nanoscale, and has been reviewed elsewhere (107). 
 
Figure 5. Design and 3D fabrication of biodegradable hydrogel microrobotic swimmers based on 
gelatin methacryloyl. (A) Empirical design of the double-helical microswimmer. (B) Computational 
fluid dynamics simulation for Reynolds number with respect to L/λ and D/R ratios, calculated for water 
at room temperature. The maximum forward swimming velocity was found with L/λ = 2.5 and D/R = 
0.5 for the given design space sweep study. (C) Alignment of the iron oxide magnetic nanoparticles 
that defines an easy axis normal to the helical axis, thereby allowing rotational motion under rotating 
magnetic fields. (D) 3D fabrication of the microswimmers using two-photon polymerization. During 
the fabrication process, a continuous magnetic field was applied to keep the nanoparticles aligned. (E) 
Optical microscope differential interference contrast (DIC) image of a microswimmer array. (F) Energy-
dispersive X-ray spectroscopy mapping of iron confirming the homogeneous embedding of the iron 
oxide magnetic nanoparticles inside the microswimmer body. Reproduced from (8). 
 
 
3. Hydrogel-based microneedles 
Microneedles represent another emerging technology platform for the delivery of therapeutics, which 
was originally investigated to enhance the penetration of drugs to the stratum corneum; there is now 
a growing interest to extend their use to other organs and tissues. Placed on a supporting base or 
within an injection system, MNs can puncture the skin seamlessly, due to their microscale dimensions, 
and deliver a range of active compounds of varying size. Microneedles can broadly be classified into 
five types: solid removable, dissolving, hollow, coated and hydrogel-forming (108); hydrogel-based 
microneedles represent the newest type, and capitalise on the biocompatibility and biodegradability 
of hydrogels (109). 
Hydrogel-forming microneedle arrays (MNs) are fabricated from aqueous blends of polymers via a 
micromoulding process in silicone moulds (110). They do not contain drugs, but swell in the skin, 
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creating porous aqueous microconduits through which drugs contained in a reservoir layer can diffuse 
and reach the dermal microcirculation; they have been shown to enhance the transdermal delivery of 
a variety of molecules for systemic absorption, as reported elsewhere (110). Donnelly et al. presented 
a transdermal patch combining lyophilised drug reservoirs of the high-dose antidiabetic drug 
metformin HCl with hydrogel-forming MN array to enhance the transdermal delivery of metformin 
(110). The MN, based on a mixture of PEG Gantrez®, a poly(methylvinylether/maleic acid) with 
molecular mass 1,500,000 Da, presented high enough mechanical strength to penetrate skin in vivo 
and in vitro, and may provide an alternative mode of delivery to help minimize gastrointestinal side 
effects associated with conventional oral delivery. 
Taking this concept further, Gu and co-workers developed a patch of MNs with a core-shell structure 
for H2O2 and pH-cascade triggered rapid insulin release for the treatment of diabetes mellitus (84,85). 
For this purpose, insulin was entrapped into degradable polymeric micelles and glucose-oxidase (GOx) 
in non-degradable micelles, which were then loaded in the crosslinked gel composing the MNs. The 
gel-based device partially dissociates, releasing insulin, when triggered by H2O2 generated during the 
oxidation of glucose by GOx, covalently tethered in the gel.  The thin sheath structure embeds 
catalase, a H2O2-scavenging enzyme, to minimize the risk of inflammation caused by H2O2 to normal 
tissues (Figure 6A). 
GelMA combines the advantageous properties of a natural polymer (gelatin), modified with 
methacrylamide or methacrylate groups, which can be crosslinked by UV light or in the presence of 
photoinitiators, and has been used widely as a versatile material for tissue engineering and a bioink 
for 3D printing, as already mentioned above with 3D printed microswimmers (8)(97). Khademhosseini 
and co-worked recently used GelMA as the matrix to prepare MNs where DOX was loaded by one step 
moulding, thus showing the promise of this material to manufacture dissolvable MNs; drug release 
occurred both through swelling and enzymatic-degradation (111) (Figure 6A). Compared with the 
burst release often observed with MNs, the GelMA-based MNs patch achieved a gradual release of 
the drug, which was a function of the crosslinking degree (longer UV exposure times), and 
demonstrate the potential of this GelMA MNs as a platform for the non-invasive delivery of a range 
of therapeutics. 
 
Figure 6. (A)-(C) Schematic of a glucose‐responsive insulin delivery system utilizing H2O2 and pH 
cascade‐responsive MN‐array patch based on nano-sized complex micelles (NCs). (A) Formation of 
insulin-loaded‐NCs (Ins-NCs) and glucose oxidase (Gox)‐NCs and mechanism of glucose‐responsive 
insulin release. (B) Schematic of H2O2‐triggered charge reduction of the polymer. (C) Schematic of the 
NC‐containing MN‐array patch with a catalase (CAT) sheath structure for in vivo insulin delivery. 
Insulin release is triggered under a hyperglycemic state. Reproduced from (84) (D) Schematic of 
GelMA-based MNs for sustained drug delivery. Gelatin was modified with MA to generate GelMA 
polymers, then DOX was mixed with the GelMA prepolymer solution and casted into the micro-
moulds. DOX‐loaded GelMA MNs were then crosslinked by UV irradiation. After drying and curing, the 




to penetrate the skin barrier and can thus release the loaded DOX into the transdermal space. 
Reproduced from (111). 
4. Polymer-free gels and hybrids 
Most of the hydrogels reported in this review have been based on polymer chains connected through 
cross-links forming a network. There are, however, an increasing number of hydrogels for drug 
delivery that depart from this traditional structure. In the field of low molecular weight gelators 
(LMWG), self-assembling short peptides, already mentioned in this article (13)(16)(23)(24)(17), have 
attracted a lot of interest, many examples of which can be found in a recent comprehensive review 
on LMWG (2). Peptide gels for drug delivery are usually based on peptides of two to seven amino 
acids, with unpolar moieties frequently attached to the peptide chain (2); they self-assemble into 
fibrous networks through a range of mechanisms, hydrogen bonds and - stacking (17), classically 
relying on β-sheets further assembling into fibres (16)(23)(112). A number of LMW hydrogelators 
which depart from peptides have also been explored for drug delivery (2). Pérez-García et al for 
instance developed a series of gels based on gemini dicationic (imidazolium) amphiphiles, which 
assembled into fibres in the presence of a small serine protease inhibitor, AEBSF-HCl (113).  
A few examples of gels for drug delivery are based on the association of colloids (for instance in 
reference (27), illustrated in Figure 1A). Bastiancich et al. designed lipid nanocapsule (LNC)-based 
injectable hydrogels for the local chemotherapy of glioblastoma (26,114), which can be implanted 
straight after surgery and provide a sustained release of a drug. LCN were prepared using a phase-
inversion process, and stabilised by non-ionic surfactants; the gel is formed by hydrogen bonds 
between the LCN when loaded with lauroyl-gemcitabine (GemC12) (26). Another example of a 
polymer-free hydrogel for drug delivery was based on mixing graphene oxide (GO) with metformin 
hydrochloride (60), an insulin sensitizer drug used in type 2 diabetes, usually administered 
transdermally by thermo-responsive microneedles or hydrogel-based microneedles (110), as 
discussed in the previous section. The gelation process is attributed to hydrogen bonds and 
electrostatic interactions between GO and metformin. The photothermal activation of GO induces the 
dissolution of the gels through irradiation with NIR light, triggering the sustained release of metformin 
(60). Another example of a particulate gel where sustained release can be triggered by ultra-sound 
was achieved with 10 nm magnetite nanoparticles (115). The iron oxide gels were obtained by direct 
gelation of a magnetite hydrosol, under the influence of a polypropylene oxide proton scavenger. The 
gel, based on Fe-O-Fe interparticle connections and comprising components that are FDA approved 
for parental administration, showed good biocompatibility and limited cytotoxicity at concentrations 
up to 207 ug·mL-1. The gels were loaded with selected organic dyes (methylene blue, to treat 
methemoglobinemia and eosin Y, an antimalaria agent, and alizarin for bone cancer treatment) and 
the drugs were released in burst mode upon ultra-sound application, due to the impact of the 
vibrations on the gel, which may be useful for fast and localised applications (115).  
Another strategy used in carrier-free gels for drug delivery is to use the drug as the gelator; for this 
purpose, they may need to be combined to a small gelator (drug conjugates) or self-assemble 
spontaneously through their own amphiphilic properties (28). A number of gels based on this method 
over the last couple of decades have been reviewed here (2). Dastidar and co-workers proposed an 
approach based on the self-assembly of NSAIDs via salt formation, recently for instance with 
indomethacin-leucine reacting with the antiviral drug amantadine to yield primary ammonium 
monocarboxylate salts, which formed anti-inflammatory, injectable gels (116), or the combination of 
ibuprofen with a series of primary amines (117).  
Alternatively, the spontaneous self-assembly of two drugs has been exploited, for instance where one 
is hydrophilic and the other hydrophobic, and both act simultaneously as the cargo and the carrier. 
With this approach, combination therapy was achieved by linking Taxol with the anticancer peptide 
tyroservatide (YSV). Taxol-EYSV spontaneously self-assembled into nanofibers upon hydrolysis with a 
high drug loading rate and controlled release behaviour, and enhanced cellular uptake (29).  
Another approach consists in making a “prodrug” to induce self-assembly, as reviewed here (118), for 
instance by conjugating the active to a short gelator, such as self-assembling peptide (which could 
itself be a drug). This was the strategy adopted by Zhong et al who developed a redox-responsive 
supramolecular gel for the delivery of 10-hydroxy camptothecin (HCPT), a cell cycle-specific 
chemotherapeutic. In this case, the gel was formed by cleaving the disulphide bond in the peptide-
drug conjugate (119). The anticancer pemetrexed (Pem) was converted to a molecular hydrogelator 
with inherent chemical exchange saturation transfer (CEST) MRI signal, and spontaneously assembled 
into filaments, thus forming an injectable theranostic supramolecular gel (10).  The range of drugs 
studied to act as components of the gels is obviously limited, with a focus on flatter, aromatic 
structures. There are also issues with the high concentrations that may be required to form gels in 
some instances, and associated toxicity (118). 
Hybrid peptide-polymer can also be used to form hydrogels and provide synergistic properties and 
new means of cross-linking. To end this section with a curiosity, Liu et al have proposed a 
nanomillipede forming self-assembling peptide as a cross-linker for dextran, through vinyl-sulfone 
reaction sites on dextran and thiol sites on the β-sheet forming peptide (120). The length of the 
nanomillipede can be controlled by exposure to ultrasounds for varying lengths of time, which, in turn, 
impacts the mechanical properties of the resulting hydrogel, thus providing a shear-thinning, self-
healing hybrid hydrogel where properties are tuned without changing the components or they 
concentration. 
 
Conclusion and Outlook 
This review has provided a glimpse of the vast repertoire of hydrogel designs that exist for drug 
delivery and highlighted the versatility of supramolecular gels (vs. traditional chemical gels) for this 
purpose, which enable stimuli-responsiveness, injectability and tuning of the release profile. Looking 
back at a review in this journal on the same topic 20 years ago (121), it is clear that the field of 
supramolecular gels, in particular based on small gelators, has considerably expanded, and new 
technologies have emerged, such as 3D printing and microfluidics, and opened new avenues for the 
design of intricate, micro- and nano-scale structures, while the complexity of architectures and 
functionality (such as the type of stimuli to trigger release, and the control over release profiles) have 
greatly advanced. 
Despite the exploding range of hydrogel designs, clinical translation has been lagging behind. The most 
impactful in terms of sales perhaps remains Medtronic INFUSE, a collagen-based gel that releases 
BMP2 for bone regeneration (1). Other products have since reached the clinic (1), but their number is 
limited, and they are usually based on simple designs and a limited library of polymers, many of natural 
origin. A number of challenges towards clinical translation are common to all DDS (costs, timescales 
of regulatory approval, etc) but the hydrated nature of hydrogels also poses additional challenges in 
terms of storage, degradation and sterilisation. The obvious question remains the trade-off between 
the complexity of the materials and subsequent regulatory hurdles, scale-up and cost.   
In terms of developing new gels, design rules are still lacking - a large part of the published studies rely 
on trial and error, and there are not enough comparisons of different hydrogel matrices for the same 
drug, using the same methods, to start establishing a rationale for DDS design. In terms of modelling 
the release profiles also a lot of progress needs to be made, in particular with regard to in vivo release.  
In conclusion, progress in technology and synthesis have broadened the arsenal of hydrogels available 
to tackle complex delivery challenges. The expanding field of biopharmaceuticals strongly suggests 
that this field will keep expanding, continuing to improve health. 
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